13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma.
A 35-year-old man with refractory cutaneous Ki-1 lymphoma was salvaged successfully with oral 13-cis-retinoic acid (1 mg/kg/day). He had a complete remission lasting for 20 months before a single nodule recurred on his skin. Excisional biopsy of the recurrent tumor revealed a distinct morphologic change, suggesting cellular differentiation toward a more benign phenotype. No significant side effects were noted except mild xerostomia, bone pain, and hyperlipidemia. The authors believe that 13-cis-retinoic acid should be considered in the treatment of cutaneous Ki-1 lymphoma.
Chow
J M
JM
Department of Internal Medicine, National Taiwan University, College of Medicine, Taipei, Republic of China.
Cheng
A L
AL
Su
I J
IJ
Wang
C H
CH
D000328:Adult; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D016130:Immunophenotyping; D017730:Ki-1 Antigen; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D017730:Ki-1 Antigen; D014212:Tretinoin